Neuroprotective Effect of Systemic And/or Intravitreal Rosuvastatin Administration in Rat Glaucoma Model

Overview

Journal Int J Ophthalmol

Specialty Ophthalmology

Date 2016 May 10

PMID 27158600

Citations 4

Authors

Metin Unlu

Zeynep Aktas

Pinar Uyar Gocun

Sevil Ozger Ilhan

Murat Hasanreisoglu

Berati Hasanreisoglu

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate the neuroprotective effect of rosuvastatin, in a rat experimental glaucoma model.

Methods: Ocular hypertension was induced in right eyes of Long-Evans rats (n=30) by cauterization of three episcleral veins. Left eyes were defined as controls. Rats were divided into five groups: oral rosuvastatin, intravitreal rosuvastatin, oral+intravitreal rosuvastatin, intravitreal sham and glaucoma without intervention. Rats were sacrificed at day 14. Retinal ganglion cell (RGC) number was assessed by histopathological analysis. Terminal deoxynucleotidyl transferase-mediated dUTP-nick end-labeling (TUNEL) staining and the expression of glial fibrillary acidic protein (GFAP) in RGC layer was also examined.

Results: A significant intraocular pressure (IOP) elevation was seen (P=0.002). Elevated IOP resulted in a significant decrease in number of RGCs in group 5 (70.33±8.2 cells/mm(2)) when compared with controls (92.50±13.72 cells/mm(2); P=0.03). The RGC number in group 1 (92.4±7.3 cells/mm(2)) was significantly higher than group 5 (P=0.03). The numbers of RGC in groups 2, 3 (57.3±8.2 cells/mm(2), 60.5±12.9 cells/mm(2)) were comparable with that of group 5 (P=0.18 and P=0.31). The apoptosis rates with TUNEL staining were also parallel to RGC number. Animals with experimentally induced glaucoma showed an increase in retinal GFAP immunoreactivity.

Conclusion: Decrease in RGC loss and apoptosis suggest the neuroprotective potential of oral rosuvastatin treatment in a rat model of ocular hypertension. However intravitreal rosuvastatin showed a contrary effect and further studies are required.

Citing Articles

Apoptosis in glaucoma: A new direction for the treatment of glaucoma (Review).

Xia Q, Zhang D Mol Med Rep. 2024; 29(5).

PMID: 38516770 PMC: 10975112. DOI: 10.3892/mmr.2024.13207.

Antibody and Protein Profiles in Glaucoma: Screening of Biomarkers and Identification of Signaling Pathways.

Auler N, Tonner H, Pfeiffer N, Grus F Biology (Basel). 2021; 10(12).

PMID: 34943212 PMC: 8698915. DOI: 10.3390/biology10121296.

Novel Use of PLGA Microspheres to Create an Animal Model of Glaucoma with Progressive Neuroretinal Degeneration.

Garcia-Herranz D, Rodrigo M, Subias M, Martinez-Rincon T, Mendez-Martinez S, Bravo-Osuna I Pharmaceutics. 2021; 13(2).

PMID: 33567776 PMC: 7915113. DOI: 10.3390/pharmaceutics13020237.

Comparison of the neuroprotective effects of brimonidine tartrate and melatonin on retinal ganglion cells.

Marangoz D, Guzel E, Eyuboglu S, Gumusel A, Seckin I, Ciftci F Int Ophthalmol. 2017; 38(6):2553-2562.

PMID: 29159432 DOI: 10.1007/s10792-017-0768-z.

References

Wang X, Tay S, Ng Y . An immunohistochemical study of neuronal and glial cell reactions in retinae of rats with experimental glaucoma. Exp Brain Res. 2000; 132(4):476-84. DOI: 10.1007/s002210000360. View

Iskedjian M, Walker J, Desjardins O, Robin A, Covert D, Bergamini M . Effect of selected antihypertensives, antidiabetics, statins and diuretics on adjunctive medical treatment of glaucoma: a population based study. Curr Med Res Opin. 2009; 25(8):1879-88. DOI: 10.1185/03007990903035083. View

Schmeer C, Kretz A, Isenmann S . Statin-mediated protective effects in the central nervous system: general mechanisms and putative role of stress proteins. Restor Neurol Neurosci. 2006; 24(2):79-95. View

Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M . Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res. 2002; 942(1-2):23-30. DOI: 10.1016/s0006-8993(02)02649-5. View

Stein J, Newman-Casey P, Talwar N, Nan B, Richards J, Musch D . The relationship between statin use and open-angle glaucoma. Ophthalmology. 2012; 119(10):2074-81. PMC: 3459293. DOI: 10.1016/j.ophtha.2012.04.029. View

Mittag T, Danias J, Pohorenec G, Yuan H, Burakgazi E, Chalmers-Redman R . Retinal damage after 3 to 4 months of elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2000; 41(11):3451-9. View

Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335(14):1001-9. DOI: 10.1056/NEJM199610033351401. View

Urcola J, Hernandez M, Vecino E . Three experimental glaucoma models in rats: comparison of the effects of intraocular pressure elevation on retinal ganglion cell size and death. Exp Eye Res. 2006; 83(2):429-37. DOI: 10.1016/j.exer.2006.01.025. View

Honjo M, Tanihara H, Nishijima K, Kiryu J, Honda Y, Yue B . Statin inhibits leukocyte-endothelial interaction and prevents neuronal death induced by ischemia-reperfusion injury in the rat retina. Arch Ophthalmol. 2002; 120(12):1707-13. DOI: 10.1001/archopht.120.12.1707. View

10.

Nezasa K, Higaki K, Matsumura T, Inazawa K, Hasegawa H, Nakano M . Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos. 2002; 30(11):1158-63. DOI: 10.1124/dmd.30.11.1158. View

11.

Vaughan C, Delanty N . Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke. 1999; 30(9):1969-73. DOI: 10.1161/01.str.30.9.1969. View

12.

Owen C, Carey I, Shah S, De Wilde S, Wormald R, Whincup P . Hypotensive medication, statins, and the risk of glaucoma. Invest Ophthalmol Vis Sci. 2010; 51(7):3524-30. DOI: 10.1167/iovs.09-4821. View

13.

Zacco A, Togo J, Spence K, Ellis A, Lloyd D, Furlong S . 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci. 2003; 23(35):11104-11. PMC: 6741057. View

14.

Shareef S, Walsh J, Sharma S . Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res. 1995; 61(1):33-44. DOI: 10.1016/s0014-4835(95)80056-5. View

15.

Baigent C, Blackwell L, Emberson J, Holland L, Reith C, Bhala N . Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753):1670-81. PMC: 2988224. DOI: 10.1016/S0140-6736(10)61350-5. View

16.

De Castro D, Punjabi O, Bostrom A, Stamper R, Lietman T, Ray K . Effect of statin drugs and aspirin on progression in open-angle glaucoma suspects using confocal scanning laser ophthalmoscopy. Clin Exp Ophthalmol. 2007; 35(6):506-13. DOI: 10.1111/j.1442-9071.2007.01529.x. View

17.

Schachter M . Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005; 19(1):117-25. DOI: 10.1111/j.1472-8206.2004.00299.x. View

18.

Sicard P, Acar N, Gregoire S, Lauzier B, Bron A, Creuzot-Garcher C . Influence of rosuvastatin on the NAD(P)H oxidase activity in the retina and electroretinographic response of spontaneously hypertensive rats. Br J Pharmacol. 2007; 151(7):979-86. PMC: 2042928. DOI: 10.1038/sj.bjp.0707322. View

19.

Kretz A, Schmeer C, Tausch S, Isenmann S . Simvastatin promotes heat shock protein 27 expression and Akt activation in the rat retina and protects axotomized retinal ganglion cells in vivo. Neurobiol Dis. 2005; 21(2):421-30. DOI: 10.1016/j.nbd.2005.08.003. View

20.

Shareef S, Salierno A, Walsh J, Sharma S . Chronic ocular hypertension following episcleral venous occlusion in rats. Exp Eye Res. 1995; 61(3):379-82. DOI: 10.1016/s0014-4835(05)80131-9. View